Abstract
In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.
Keywords:
Australia; epidemiology; influenza; influenza-like illness - ILI; surveillance; vaccines and immunisation; viral infections.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Australia / epidemiology
-
Child
-
Child, Preschool
-
Female
-
Humans
-
Influenza A Virus, H1N1 Subtype / genetics
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza A Virus, H3N2 Subtype / genetics
-
Influenza A Virus, H3N2 Subtype / immunology*
-
Influenza A Virus, H3N2 Subtype / isolation & purification
-
Influenza B virus / genetics
-
Influenza B virus / immunology*
-
Influenza B virus / isolation & purification
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / immunology
-
Influenza, Human / epidemiology*
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Laboratories
-
Male
-
Middle Aged
-
Outcome Assessment, Health Care
-
RNA, Viral / genetics
-
Seasons
-
Sentinel Surveillance*
-
Sequence Analysis, DNA
-
Vaccination / statistics & numerical data
-
Vaccine Potency*
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / immunology
-
Young Adult
Substances
-
Influenza Vaccines
-
RNA, Viral
-
Vaccines, Inactivated